Literature DB >> 15155834

Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene.

Kyle Christian1, Matti Lang, Patrick Maurel, Françoise Raffalli-Mathieu.   

Abstract

The human xenobiotic-metabolizing enzyme cytochrome P450, CYP2A6, catalyzes the bioactivation of a number of carcinogens and drugs and is overexpressed in cases of liver diseases, such as cirrhosis, viral hepatitis, and parasitic infestation, and in certain tumor cells. This suggests that CYP2A6 may be a major liver catalyst in pathological conditions. In the present study, we have addressed molecular mechanisms underlying the regulation of the CYP2A6 gene. We present evidence of several proteins present in human hepatocytes that interact specifically with the 3'-untranslated region (UTR) of CYP2A6 mRNA. Biochemical and immunological evidence show that the RNA-protein complex of highest intensity contains the heterogeneous nuclear ribonucleoprotein (hnRNP) A1 or a closely related protein. Mapping of the hnRNP A1 binding site within CYP2A6 3'-UTR reveals that the smallest portion of RNA supporting significant binding consists of 111 central nucleotides of the 3'-UTR. Our studies also indicate that hnRNPA1 from HepG2 cancer cells exhibits modified binding characteristics to the CYP2A6 3'-UTR compared with primary hepatocytes. We found that the level of CYP2A6 mRNA remains high in conditions of impaired transcription in primary human hepatocytes, showing that CYP2A6 expression can be affected post-transcriptionally in conditions of cellular stress. Our results indicate that the post-transcriptional regulation involves interaction of the hnRNP A1 protein with CYP2A6 mRNA. The present data suggest that hnRNPA1 is a critical regulator of expression of the human CYP2A6 gene and support the notion that this P450 isoform may be of particular significance in stressed human liver cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155834     DOI: 10.1124/mol.65.6.1405

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

Review 1.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

2.  Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes.

Authors:  Alec W R Langlois; Ahmed El-Boraie; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Jo Knight; Steven E Scherer; Meghan J Chenoweth; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2022-02-21       Impact factor: 2.000

3.  Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.

Authors:  J C Mwenifumbo; C N Lessov-Schlaggar; Q Zhou; R E Krasnow; G E Swan; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

4.  Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.

Authors:  Lin Yang; Yi Yang; Qiong Qin; Aiping Zhou; Jianjun Zhao; Jinwan Wang; Chang Shu; Xinghua Yuan; Songnian Hu
Journal:  Mol Clin Oncol       Date:  2013-09-23

5.  A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder.

Authors:  B S Pickard; H M Knight; R S Hamilton; D C Soares; R Walker; J K F Boyd; J Machell; A Maclean; K A McGhee; A Condie; D J Porteous; D St Clair; I Davis; D H R Blackwood; W J Muir
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-29       Impact factor: 11.205

Review 6.  mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer.

Authors:  Dobrochna Dolicka; Cyril Sobolewski; Marta Correia de Sousa; Monika Gjorgjieva; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2020-09-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.